<DOC>
	<DOCNO>NCT00710827</DOCNO>
	<brief_summary>To evaluate safety efficacy Nebido compare placebo elderly men age 50 symptomatic late onset hypogonadism</brief_summary>
	<brief_title>Nebido Versus Placebo Elderly Men With Typical Symptoms Late Onset Hypogonadism Over Period 54 Weeks</brief_title>
	<detailed_description>Explorative objective : Change grip strength ( Subgroup : optional site experience test muscle function ) ; Change physical performance test i.e . low limb muscle strength ( subgroup ; optional site experience test muscle function ) . Please note 2 explorative objective mention must perform together . All measure baseline , week 30 , week 54 , safety measure . Safety parameter Prostate safety : digital rectal examination ( DRE ) Measured screening , week 30+ 54 , safety measure . International prostate symptom score ( IPSS ) : International prostate symptom score ( IPSS ) Measured screening , week 18 , 30 , 42 , 54 , safety measure . Laboratory test lipid ( total cholesterol , LDL-cholesterol , HDL-cholesterol triglyceride ) liver function test ( aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) ) Measured screening , week 6 , 18 , 30 , 42 , 54 , safety measure . Standard laboratory test androgen treatment : prostate specific antigen ( PSA ) ; hemoglobin ; hematocritMeasured screening , week 6 , 18 , 30 , 42 , 54 , safety measureAdverse eventsMeasured screening , baseline , week 6 , 18 , 30 , 42 , 54Vital signsMeasured screening , week 18 , 30 , 42 , 54 , safety measure .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Men age 50 year older Symptomatic hypogonadism define ) b ) : ) Total testosterone 12nmol/l b ) Aging male symptom score 36 Willing avoid significant change pattern physical exercise lifestyle duration study Willing voluntarily sign statement inform consent participate study . Use androgen therapy anabolic steroid Suspicion know history liver tumor , prostate breast cancer Hypersensitivity active substance excipients NEBIDO e.g . Benzyl benzoate castor oil . Hypercalcemia accompany malignant tumor Blood coagulation irregularity present increase risk bleed intramuscular injection sleep apnea Polycythemia Hematocrit level &gt; 50 % entry study ( i.e . screen visit/visit 1 ) Patients use 5areductase inhibitor finasteride dutasteride exclude study . Prolactin level &gt; 25ng/ml Organic hypothalamicpituitary pathology Prostate specific antigen ( PSA ) level ≥ 4ng/ml Severe symptomatic benign prostatic hyperplasia ( IPSS sum score ≥ 20 ) Epilepsy adequately control treatment Migraine adequately control treatment Patients require undergoing fertility treatment Any clinically significant chronic disease might , opinion investigator , compromise patient 's safety interfere evaluation , preclude completion trial ( e.g . hemochromatosis , chronic lung disease , chronic malabsorption disease ) Known history alcohol drug abuse Medical , psychiatric condition compromise patient 's ability understand patient information , give informed consent , comply trial protocol , complete study . Hypertension adequately control therapy Severe cardiac , hepatic renal insufficiency Coronary heart disease stabilize therapy assess investigator Metal implant body ( metal implant head exclude patient participation ) Concomitant participation another clinical trial within 1 month entry study ( i.e . randomize take study medication ) .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>NEBIDO ,</keyword>
	<keyword>Hypogonadism ,</keyword>
	<keyword>Symptomatic late onset ,</keyword>
	<keyword>Testosterone deficiency</keyword>
</DOC>